查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596139

快速诊断市场：按产品和应用分类 - 2025 年至 2030 年全球预测

Rapid Diagnostics Market by Product (OTC Rapid Diagnostics Test, Professional Rapid Diagnostics Test), Application (Blood Glucose Rapid Diagnostics, Cardiometabolic Rapid Diagnostics, Coagulation Rapid Diagnostics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年快速诊断市场规模为304.2亿美元，预计2024年将达340.3亿美元，复合年增长率为11.95%，2030年将达670.5亿美元。

快速诊断市场是医疗产业的一个重要子集，专注于提供快速、准确的诊断结果，从而显着改善患者的治疗结果。该市场包括侧流免疫检测、就地检验套件和分子诊断设备等技术和产品，每种技术和产品都能够在临床环境中及时做出决策。快速诊断系统的需求在于其能够立即提供结果、减少患者等待时间并促进快速治疗性介入。这些技术对于管理 COVID-19 等感染疾病爆发以及心血管和呼吸道疾病等需要紧急诊断的疾病至关重要。主要最终用户包括医院、临床实验室、居家医疗机构和研究机构。

主要市场统计
基准年[2023] 304.2亿美元
预测年份 [2024] 340.3亿美元
预测年份 [2030] 670.5亿美元
复合年增长率（%） 11.95%

诊断市场的快速成长受到就地检验需求不断增长、感染疾病爆发不断增加以及向个人化医疗转变的影响。此外，技术进步和人工智慧在诊断过程中的整合提供了快速成长的机会。公司可以透过投资研发来利用这些趋势，开发更可携式、更具成本效益且易于使用的诊断工具。开发同时检测多种疾病状态的多重检测也是一个策略方向。然而，监管障碍、高成本和一些快速测试的准确性有限等挑战限制了成长。此外，对强大医疗基础设施的需求阻碍了资源匮乏地区的市场扩张。

创新应着重于提高诊断准确性、降低成本、实施数位健康解决方案、改善供应链物流并广泛应用。与高科技公司合作开发提供资料分析和决策支援系统的智慧诊断可以呈现新的市场优势领域。竞争格局是由技术进步驱动的，这意味着需要持续创新才能维持市场地位。能够成功平衡产品创新与成本和准确性限制的公司可能会在这个不断发展的市场中取得成功。

市场动态：揭示快速发展的快速诊断市场的关键市场洞察

供需的动态交互作用正在改变快速诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 感染疾病流行的蔓延
    • 目标疾病盛行率增加
    • 政府扶持政策
    • 由于早期诊断意识的增强，对分散环境中快速诊断测试的需求增加
  • 市场限制因素
    • 对新的快速诊断测试缺乏认识
  • 市场机会
    • 扩大在诊断、病患管理、流行病学和筛检的应用
    • 床边诊断测试的需求不断增长
    • 加大投融资资金筹措，快速诊断产品开发
  • 市场问题
    • 与明确的中心实验室方法缺乏一致性

波特五力：驾驭快速诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对快速诊断市场的影响

外部宏观环境因素在塑造快速诊断市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解快速诊断市场的竞争格局

对快速诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：快速诊断市场供应商绩效评估

FPNV 定位矩阵是评估快速诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製快速诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，快速诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病的传播
      • 目标疾病发生率增加
      • 政府扶持政策
      • 随着人们对早期诊断的认识不断增强，对分散式环境中快速诊断测试的需求不断增加。
    • 抑制因素
      • 对新的快速诊断测试缺乏认识
    • 机会
      • 更多采用诊断、患者管理、流行病学和筛检
      • 床边诊断测试的需求增加
      • 增加快速诊断产品开发的投资和资金
    • 任务
      • 与明确的中心实验室方法缺乏一致性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章快速诊断市场：副产品

  • 介绍
  • OTC快速诊断测试
  • 专业人士的快速诊断测试

第七章快速诊断市场：按应用

  • 介绍
  • 血糖值快速诊断
  • 快速心臟代谢诊断
  • 凝血快速诊断
  • 粪便潜血快速诊断
  • 感染疾病快速诊断
  • 妊娠及不孕症快速诊断
  • 快速毒物诊断

第八章美洲快速诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太快速诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲快速诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Abingdon Health Group
  • ACON Laboratories, Inc.
  • AgaMatrix, Inc.
  • Arbor Vita Corporation
  • Assure Tech.（Hangzhou）Co., Ltd.
  • BioMedomics Inc.
  • Biomerica
  • bioMerieux SA
  • Biopanda Reagents Ltd.
  • Cellex Incorporated
  • Chembio Diagnostics, Inc.
  • Clinical Reference Laboratory, Inc.
  • EKF DIAGNOSTICS HOLDINGS PLC
  • F. Hoffmann-La Roche Ltd.
  • Healgen Scientific LLC
  • Meridian Bioscience, Inc.
  • Sekisui Diagnostics Group
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035AB9C0DA79

The Rapid Diagnostics Market was valued at USD 30.42 billion in 2023, expected to reach USD 34.03 billion in 2024, and is projected to grow at a CAGR of 11.95%, to USD 67.05 billion by 2030.

The rapid diagnostics market is an essential subset of the healthcare industry, focused on providing quick and accurate diagnostic results that significantly improve patient care outcomes. This market includes technologies and products like lateral flow immunoassays, point-of-care testing kits, and molecular diagnostics devices, each enabling timely decision-making in clinical settings. The necessity of rapid diagnostic systems lies in their ability to deliver immediate results, reducing patient wait times and facilitating faster treatment interventions. These technologies have been pivotal in managing infectious disease outbreaks, like COVID-19, and other conditions requiring urgent diagnosis, such as cardiovascular and respiratory diseases. The primary end-users include hospitals, clinical laboratories, home care settings, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 30.42 billion
Estimated Year [2024] USD 34.03 billion
Forecast Year [2030] USD 67.05 billion
CAGR (%) 11.95%

Market growth in rapid diagnostics is influenced by the rising demand for point-of-care testing, increased prevalence of infectious diseases, and a shift toward personalized medicine. Additionally, technological advancements and the integration of artificial intelligence in diagnostic processes offer burgeoning opportunities. Companies can leverage these trends by investing in research and development to create more portable, cost-effective, and user-friendly diagnostic tools. Developing multiplex assays to test for multiple conditions simultaneously is another strategic direction. However, challenges such as regulatory hurdles, high costs, and the limited accuracy of some rapid testing methods pose limitations to growth. Furthermore, market expansion in low-resource settings is impeded by the need for robust healthcare infrastructures.

Innovation should focus on enhancing diagnostic accuracy, reducing costs, incorporating digital health solutions, and improving supply chain logistics to ensure widespread accessibility. Collaboration with tech companies to develop smart diagnostics that provide data analytics and decision support systems can present new areas of market advantage. The nature of the rapid diagnostics market suggests a competitive landscape driven by technological advancements, underscoring the necessity for continuous innovation to maintain market relevance. Businesses that can successfully balance product innovation with cost and accuracy constraints will likely thrive in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rapid Diagnostics Market

The Rapid Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious diseases
    • Increasing incidence of target conditions
    • Supportive government policies
    • Rising demand for rapid diagnostic tests in decentralized settings along with rising awareness regarding early diagnosis
  • Market Restraints
    • Lack of awareness regarding newer rapid diagnostic tests
  • Market Opportunities
    • Growing adoption for diagnosis, patient management, epidemiology, and screening
    • Increased demand for bedside diagnostic testings
    • Growing investments and funding for rapid diagnostic product development
  • Market Challenges
    • Lack of alignment with definitive central lab methods

Porter's Five Forces: A Strategic Tool for Navigating the Rapid Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rapid Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rapid Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rapid Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rapid Diagnostics Market

A detailed market share analysis in the Rapid Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rapid Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rapid Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rapid Diagnostics Market

A strategic analysis of the Rapid Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rapid Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abingdon Health Group, ACON Laboratories, Inc., AgaMatrix, Inc., Arbor Vita Corporation, Assure Tech.(Hangzhou) Co., Ltd., BioMedomics Inc., Biomerica, bioMerieux S.A., Biopanda Reagents Ltd., Cellex Incorporated, Chembio Diagnostics, Inc., Clinical Reference Laboratory, Inc., EKF DIAGNOSTICS HOLDINGS PLC, F. Hoffmann-La Roche Ltd., Healgen Scientific LLC, Meridian Bioscience, Inc., Sekisui Diagnostics Group, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rapid Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across OTC Rapid Diagnostics Test and Professional Rapid Diagnostics Test.
  • Based on Application, market is studied across Blood Glucose Rapid Diagnostics, Cardiometabolic Rapid Diagnostics, Coagulation Rapid Diagnostics, Fecal Occult Blood Rapid Diagnostics, Infectious Diseases Rapid Diagnostics, Pregnancy & Fertility Rapid Diagnostics, and Toxicology Rapid Diagnostics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases
      • 5.1.1.2. Increasing incidence of target conditions
      • 5.1.1.3. Supportive government policies
      • 5.1.1.4. Rising demand for rapid diagnostic tests in decentralized settings along with rising awareness regarding early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness regarding newer rapid diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing adoption for diagnosis, patient management, epidemiology, and screening
      • 5.1.3.2. Increased demand for bedside diagnostic testings
      • 5.1.3.3. Growing investments and funding for rapid diagnostic product development
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of alignment with definitive central lab methods
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rapid Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. OTC Rapid Diagnostics Test
  • 6.3. Professional Rapid Diagnostics Test

7. Rapid Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Blood Glucose Rapid Diagnostics
  • 7.3. Cardiometabolic Rapid Diagnostics
  • 7.4. Coagulation Rapid Diagnostics
  • 7.5. Fecal Occult Blood Rapid Diagnostics
  • 7.6. Infectious Diseases Rapid Diagnostics
  • 7.7. Pregnancy & Fertility Rapid Diagnostics
  • 7.8. Toxicology Rapid Diagnostics

8. Americas Rapid Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Rapid Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Rapid Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abingdon Health Group
  • 3. ACON Laboratories, Inc.
  • 4. AgaMatrix, Inc.
  • 5. Arbor Vita Corporation
  • 6. Assure Tech.(Hangzhou) Co., Ltd.
  • 7. BioMedomics Inc.
  • 8. Biomerica
  • 9. bioMerieux S.A.
  • 10. Biopanda Reagents Ltd.
  • 11. Cellex Incorporated
  • 12. Chembio Diagnostics, Inc.
  • 13. Clinical Reference Laboratory, Inc.
  • 14. EKF DIAGNOSTICS HOLDINGS PLC
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Healgen Scientific LLC
  • 17. Meridian Bioscience, Inc.
  • 18. Sekisui Diagnostics Group
  • 19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RAPID DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. RAPID DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RAPID DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RAPID DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY OTC RAPID DIAGNOSTICS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL RAPID DIAGNOSTICS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD GLUCOSE RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOMETABOLIC RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY FECAL OCCULT BLOOD RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TOXICOLOGY RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023